PARADIGM BIOCAPITAL ADVISORS LP
Q2 2025 Form 13-F
NEW YORK, NEW YORK
CIK 0001855655
· CRD 312544
· SEC-registered investment adviser
$2.3B Reported Value Total
PARADIGM BIOCAPITAL ADVISORS LP reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $3,054,844,396, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $4.1B gross asset value
Hedge Fund: $4.1B
Source: Form ADV filed 2026-08-27
Reported value
$2.3B
Quarter over quarter
-0.4%
Holdings
28
Top-10 concentration
72.3%
Key People
Form ADV owners & control persons
Dr. Senai Nmn Asefaw
CHIEF INVESTMENT OFFICER / LIMITED PARTNER
David Kyungtaek Kim
CHIEF OPERATING OFFICER / CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2025 13F record
Q2 2025 13F filing summary
| Period of report | June 30, 2025 |
|---|---|
| Filed | August 14, 2025 |
| Form | 13F-HR |
| Reported value | $2.3B |
| Positions | 28 |
| Change in reported value | +7.3% |
| New positions | 6 |
| Exited positions | 5 |
| Position turnover | 33.3% |
| Top-10 concentration | 72.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
28 | $5.3B |
|
Q1 2026 13F
Filed May 15, 2026
|
35 | $4.9B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
29 | $3.9B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
33 | $3.5B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
28 | $2.3B |
|
Q1 2025 13F
Filed May 15, 2025
|
27 | $2.2B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
28 | $2.9B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
31 | $3.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
35 | $2.6B |
|
Q1 2024 13F
Filed May 15, 2024
|
34 | $2.8B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
29 | $2.1B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
29 | $1.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
29 | $1.3B |
|
Q1 2023 13F
Filed May 15, 2023
|
25 | $1.1B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
23 | $851.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
27 | $750.1M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
23 | $501.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
25 | $378.2M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
24 | $350.2M |
Top 20 holdings · Q2 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | NUVL NUVALENT INC | $402.1M | 17.17% |
| 2 | ACLX ARCELLX INC | $306.1M | 13.07% |
| 3 | MRUS MERUS N V | $225.2M | 9.62% |
| 4 | RVMD REVOLUTION MEDICINES INC | $224.2M | 9.57% |
| 5 | TARS TARSUS PHARMACEUTICALS INC | $120.6M | 5.15% |
| 6 | PCVX VAXCYTE INC | $109.7M | 4.68% |
| 7 | ONC BEONE MEDICINES LTD | $84.2M | 3.59% |
| 8 | EWTX EDGEWISE THERAPEUTICS INC | $80.5M | 3.44% |
| 9 | COGT COGENT BIOSCIENCES INC | $74.3M | 3.17% |
| 10 | JANX JANUX THERAPEUTICS INC | $67.5M | 2.88% |
| 11 | CRNX CRINETICS PHARMACEUTICALS IN | $67.4M | 2.88% |
| 12 | IRON DISC MEDICINE INC | $64.1M | 2.74% |
| 13 | SRRK SCHOLAR ROCK HLDG CORP | $56.7M | 2.42% |
| 14 | LENZ LENZ THERAPEUTICS INC | $50.3M | 2.15% |
| 15 | BBIO BRIDGEBIO PHARMA INC | $41.7M | 1.78% |
| 16 | APGE APOGEE THERAPEUTICS INC | $41.6M | 1.78% |
| 17 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | $41.5M | 1.77% |
| 18 | ALKS ALKERMES PLC | $39.4M | 1.68% |
| 19 | VRDN VIRIDIAN THERAPEUTICS INC | $38.3M | 1.64% |
| 20 | AGIO AGIOS PHARMACEUTICALS INC | $38.0M | 1.62% |
Values as reported on the Q2 2025 Form 13F. Every position is in the holdings table below.